Obsidian Therapeutics, Inc. OBX
12.36 USD -0.20 (-1.59%)
Regular-session close
12.36 0.00 0.00%
After hours · Nov 16, 4:26 PM ET
11.85 Day range 12.71
9.60 52-week range 49.97
- YTD
- -29.37%
- 1 year
- -29.37%
News
benzinga.com Obsidian Therapeutics Q3 EPS $(1.23) Up From $(14.77) YoY Obsidian Therapeutics (NASDAQ:OBX) reported quarterly losses of $(1.23) per share. This is a 91.67 percent increase over losses of $(14.77) per share from the same period last year.
businesswire.com Obsidian Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc. (“Obsidian”) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Karyopharm Therapeutics (NASDAQ:KPTI) stock moved upwards by 10.0% to $0.04 during Monday's after-market session. The company's market cap stands at $1.2 million. Fractyl Health (NASDAQ:GUTS)…
benzinga.com Dole Posts Downbeat Q3 Results, Joins NVIDIA And Other Big Stocks Moving Lower In Monday’s Pre-Market Session U.S. futures rose, but Dole fell 8.3% after missing Q3 estimates. CEVA, CYPH, CLNE, SMRT, OBX, ASST, NVDA and BMNR also declined premarket.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Obsidian Therapeutics (NASDAQ:OBX) stock increased by 27.7% to $12.26 during Friday's regular session. The company's market cap stands at $593.0 million. TransMedics Group (NASDAQ:TMDX)…benzinga.com Obsidian Therapeutics To Present Updated Data In Participants With Immune-Checkpoint Inhibitor-Resistant Advanced Melanoma From Phase 1 Trial, Phase 1/2 Agni-01 Multicenter Trial Of Amsokigene Autoleucel At Society For Immunotherapy Of Cancer Obsidian Therapeutics, Inc. (NASDAQ:OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell…
